Table 1 Epidemiological, clinical and social characteristics.
New diagnosis (n = 203) | Follow up (n = 297) | Overall (n = 500) | |||||||
|---|---|---|---|---|---|---|---|---|---|
NGO (n = 21) | No NGO (n = 182) | p | NGO (n = 67) | No NGO (n = 230) | p | NGO (n = 88) | No NGO (n = 412) | p | |
Age (years) | 30 (25–38) | 36 (30–45) | 0.007 | 30 (28–36) | 37 (30–49) | 0.0000 | 30 (28–36) | 37 (30–47) | 0.0000 |
Sex | |||||||||
Men | 20 (95%) | 154 (85) | 0.18 | 63 | 191 | 0.024 | 83 (94%) | 345 (84%) | 0.0103 |
Women | 0 | 21 (11%) | 78 | (94%) | (83%) | 5 | 0 | 50 (12%) | 0.0006 |
Trans women | 1 (5%) | 7 (4%) | 0.1002 | 0 | 29 (13%) | 0.0022 | 5(6%) | 17 (4%) | 0.5184 |
0.8382 | 4 (6%) | 10 (4%) | 0.5814 | ||||||
Country of origin | |||||||||
Spain | 3 (14%) | 81 (44%) | 0.0078 | 0 | 73 (32%) | 0.0000 | 3 (3%) | 154 (37%) | 0.0000 |
Rest of Europe | 0 | 5 (3%) | 0.4418 | 2 (3%) | 15 (6%) | 0.2728 | 2 (2%) | 20 (5%) | 0.2838 |
Venezuela | 7 (33%) | 24 (13%) | 0.0151 | 18 (27%) | 38 (16%) | 0.0568 | 25(29%) | 62 (15%) | 0.0027 |
Colombia | 4 (19%) | 9 (5%) | 0.0124 | 26 (39%) | 24 (10%) | 0.0000 | 30 (34%) | 33 (8%) | 0.0000 |
Peru | 3 (15%) | 14 (8%) | 0.3017 | 7 (10%) | 18 (8%) | 0.4964 | 10 (12%) | 32 (8%) | 0.2695 |
Rest of latinamerica | 4 (19%) | 32 (18%) | 0.8678 | 13 (19%) | 50 (22%) | 0.6806 | 17 (19%) | 82 (20%) | 0.9006 |
Morroco | 0 | 10 (5%) | 0.2706 | 0 | 2 (1%) | 0.4438 | 0 | 12 (3%) | 0.1051 |
Subsaharan Africa | 0 | 4 (2%) | 0.4926 | 0 | 6 (3%) | 0.1817 | 0 | 10 (2%) | 0.1399 |
Others | 0 | 3 (2%) | 0.5534 | 1 (2%) | 4 (2%) | 0.8902 | 1 (1%) | 7 (2%) | 0.7026 |
Time in Spain (months) | 46 (13–118) | 9 (7–15) | 0.003 | 7 (2–55) | 3 (1–7) | 0.0000 | 5 (1–9) | 28 (4–96) | 0.0000 |
Initial Healthcare coverage | |||||||||
No | 10 (48%) | 14 (8%) | 0.0000 | 59 (88%) | 48 (21&) | 0.0000 | 69 (78%) | 62 (15%) | 0.0000 |
Final Healthcare coverage | |||||||||
No | 6 (29%) | 8 (4%) | 0.0000 | 17 (25%) | 19 (8%) | 0.0002 | 23 (26%) | 27 (7%) | 0.000 |
Referred from | |||||||||
Emergency room | 40 (22%) | 31 (14%) | 71 (17%) | ||||||
Other hospital ward | 52 (29%) | 22 (10%) | 74 (18%) | ||||||
Primary Care | 48 (26%) | 47 (20%) | 95 (23%) | ||||||
STI Clinic | 16 (9%) | 9 (4%) | 25 (6%) | ||||||
Other hospital in Madrid | 6 (3%) | 26 (11%) | 32 (8%) | ||||||
Other hospital outside Madrid | 0 | 26 (11%) | 26 (6%) | ||||||
Other/unkown | 20 (11%) | 69 (30%) | 89 (22%) | ||||||
Time of HIV Infection (years) | 5 (2–8) | 7 (4–12) | 0.001 | ||||||
Risk group | |||||||||
MSM | 21 (100%) | 133 (76%) | 0.0123 | 65 (98.5%) | 166 (75%) | 0.0000 | 86 (99% | 299 (75%) | 0.0000 |
Hetero | 0.0258 | 32 (14%) | 0.0040 | 1 (1%) | 66 (17%) | 0.0002 | |||
IVDU | 34 (20%) | 0.5442 | 1 (1.5%) | 21 (9%) | 0.0096 | 24 (6%) | 0.0187 | ||
MSM/IVDU | 3 (2%) | 0.4827 | 2 (1%) | 0.4401 | 6 (1.5%) | 0.2486 | |||
Other/unknown | 4 (2%) | 0.0123 | 2 (1%) | 0.4401 | 2 (0.5%) | 0.5071 | |||
Prior AIDS condition | 1 (5%) | 28 (15%) | 0.1878 | 3 (5%) | 28 (12%) | 0.0698 | 4 (5%) | 56 (14%) | 0.0178 |
Basal CD4 count | 394 (256–537) | 358 (195–555) | 0.571 | 665 (505–842) | 624 (402–879) | 0.380 | |||
Basal Viral load-log | 4.5 (4–5) | 5 (4–6) | 0.080 | ||||||
Detectable viral load for ART interruption at recruitment | 10 (15%) | 54 (24%) | 0.0894 | ||||||
Delay on ART initiation (days) | 6 (2–21) | 14 (7–34) | 0.054 | ||||||
AIDS condition at recruitment | 1 (33%) | 19 (14%) | 0.3486 | 2 (33%) | 7 (5%) | 0.0029 | 3 (33%) | 26 (9%) | 0.0159 |
STD basal | 9 (43%) | 52 (29%) | 0.1819 | 13 (19%) | 44 (19%) | 0.9725 | 22 (25%) | 96 (23%) | 0.7510 |
Quantiferon+ | 3 (15%) | 16 (10%) | 0.4545 | 8 (13%) | 23 (12%) | 0.8897 | 11 (13%) | 39 (11%) | 0.5392 |
Active TB | 1 (5%) | 3 (2%) | 0.3337 | 1 (1.5%) | 2 (1%) | 0.6551 | 2 (2%) | 5 (1%) | 0.4433 |
No HIV related diseases | |||||||||
Cardiovascular | 0 | 3 (2%) | 0.5522 | 0 | 7 (3%) | 0.1466 | 0 | 10 (2%) | 0.1384 |
Oncological | 0 | 6 (3%) | 0.3970 | 1 (1.5%) | 6 (3%) | 0.5902 | 1 (1%) | 12 (3%) | 0.3378 |
Hypertension | 1 (5%) | 9 (5%) | 0.9664 | 0 | 17 (8%) | 0.0213 | 1 (1%) | 26 (6%) | 0.0500 |
Diabetes mellitus | 0 | 4 (2%) | 0.4914 | 0 | 8 (4%) | 0.1201 | 0 | 12 (3%) | 0.1038 |
Dyslipidemia | 0 | 4 (2%) | 0.4914 | 6 (9%) | 28 (12%) | 0.4536 | 6 (7% | 32 (8%) | 0.7474 |
Nephropathy | 0 | 2 (1%) | 0.6283 | 0 | 2 (1%) | 0.4418 | 0 | 4 (1%) | 0.3516 |
Respiratory disease | 0 | 4 (2%) | 0.4902 | 1 (1.5%) | 5 (2%) | 0.7210 | 1 (1%) | 9 (2%) | 0.5174 |
Liver disease | 0 | 5 (3%) | 0.4406 | 0 | 27 (12%) | 0.0031 | 0 | 32 (8%)) | 0.0067 |
STD while follow-up | 4 (19%) | 34 (19%) | 0.9763 | 11 (16%) | 39 (17%) | 0.8614 | 15 (17%) | 73 (18%) | 0.7977 |
Closure | |||||||||
1: Active follow-up | 16 (76%) | 156 (86%) | 0.2506 | 50 (75%) | 179 (78%) | 0.5834 | 335 (82%) | 66 (75%) | 0.1775 |
2: Move to other region | 1 (5%) | 9 (5%) | 0.9707 | 3 (5%) | 19 (8%) | 0.2981 | 28 (7%) | 4 (5%) | 0.4336 |
3: Move to other country | 1 (5%) | 3 (1.5%) | 0.3310 | 0 | 1 (0.5%) | 0.5888 | 4 (1%) | 1 (1%) | 0.8874 |
4: Return to original country | 0 | 0 | 0 | 3 (1%) | 0.3474 | 3 (1%) | 0 | 0.4220 | |
5: Lost of follow-up | 2 (9%) | 8 (4%) | 0.3039 | 12 (18%) | 21 (9%) | 0.0442 | 29 (7%) | 14 (16%) | 0.0071 |
6: Jail | 0 | 1 (0.5%) | 0.7335 | 0 | 1 (0.5%) | 0.5888 | 2 (0.5%) | 0 | 0.5125 |
7: Death | 0 | 2 (1%) | 0.6293 | 0 | 0 | 0 | 2 (0.5%) | 0 | 0.5125 |
8. Change of hospital in Madrid | 1 (5%) | 3 (2%) | 0.3310 | 2 (3%) | 6 (3%) | 0.8670 | 9 (2%) | 3 (3%) | 0.4956 |
